Kyle Diamantas is leading the U.S. Food and Drug Administration as acting commissioner following the resignation of Marty Makary [1, 2].
The transition places a little-known legal professional at the head of the federal agency responsible for public health and food safety. Diamantas previously served as the agency's top food official, a role that initially drew scrutiny due to his lack of a deep profile within the food-industry community [1, 2].
Diamantas, a Florida attorney, was appointed to the FDA's food leadership position in 2025 [1]. His rise within the agency occurred under the Trump administration, which selected him to fill the vacancy [1, 2].
Industry observers initially questioned the appointment of a lawyer to a technical leadership role. STAT News said, "People in the food world didn’t know what to expect when the Trump administration appointed a little‑known Florida attorney as the FDA’s top food official in 2025" [1].
Reports regarding the timing of the transition vary slightly. LiveMint, citing Reuters, said Diamantas was expected to take over leadership in an acting capacity after Makary's exit [2]. However, other reports indicate he has already risen to lead the agency in that role [1].
Diamantas now manages the agency's broad mandate from its headquarters in Washington, D.C. His tenure as acting commissioner follows a period of leadership change that has shifted the agency's internal dynamics, and its relationship with industry stakeholders [1].
“Kyle Diamantas is leading the U.S. Food and Drug Administration as acting commissioner”
The appointment of a lawyer rather than a scientist or career public health official to lead the FDA signals a potential shift in how the agency approaches regulation and enforcement. By placing a legal professional in the acting commissioner role, the administration may be prioritizing regulatory interpretation and legal strategy over traditional technical expertise.
